Ricerc@Sapienza

A new chiral stationary phase was designed by
introducing 9-amino-9-deoxy-9-epiquinine, one of the
most versatile organocatalysts in asymmetric synthesis, as
chiral scaffold. The derivatization of its amino group with
the 3,5-dinitrobenzoyl (DNB) fragment provided hydrogen
bonding and ?–? donor/acceptor systems in addition to
the quinoline and quinuclidine moieties having two nitrogen
atoms with different basicities. The selector offers
multiple interaction sites in both typical of the Pirkle-type

This review article is aimed at providing an overview of the current market of chiral drugs by exploring which is the nowadays tendency, for the pharmaceutical industry, either to exploit the chiral switching practice from already marketed racemates or to develop de novo enantiomerically pure compounds. A concise illustration of the main techniques developed to assess the absolute configuration (AC) and enantiomeric purity of chiral drugs has been given, where greater emphasis was placed on the contribution of enantioselective chromatography (HPLC, SFC and UHPC).